Information Provided By: 
Fly News Breaks for April 30, 2019
ELAN, PETX
Apr 30, 2019 | 07:57 EDT
As previously reported, Credit Suisse analyst Erin Wright downgraded Aratana Therapeutics (PETX) to Neutral from Outperform following Elanco's (ELAN) proposed acquisition of the company. The analyst also lowered her price target on Aratana Therapeutics shares to $4.85 from $5 on the expectation of successful deal completion by Q2 at $4.75/share.
News For PETX;ELAN From the Last 2 Days
There are no results for your query PETX;ELAN
